Presentation of tumour antigens by dendritic cells and challenges faced.

[1]  Arnaud M. Didierlaurent,et al.  AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity1 , 2009, The Journal of Immunology.

[2]  J. Tschopp,et al.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors , 2009, Nature Medicine.

[3]  Martin A. Cheever,et al.  The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research , 2009, Clinical Cancer Research.

[4]  R. Hromas,et al.  Metnase mediates chromosome decatenation in acute leukemia cells. , 2009, Blood.

[5]  P. Schellhammer,et al.  Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer , 2009, Cancer.

[6]  C. Berking,et al.  Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. , 2009, The Journal of clinical investigation.

[7]  E. Maraskovsky,et al.  Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant , 2009, Immunology and cell biology.

[8]  D. Green,et al.  Immunogenic and tolerogenic cell death , 2009, Nature Reviews Immunology.

[9]  Christian Wiesmann,et al.  Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. , 2009, The Journal of clinical investigation.

[10]  H. Wagner.  The immunogenicity of CpG-antigen conjugates. , 2009, Advanced drug delivery reviews.

[11]  R. Greil,et al.  PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. , 2009, Blood.

[12]  Y. Refaeli,et al.  Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. , 2009, Blood.

[13]  K. Shortman,et al.  Improving vaccines by targeting antigens to dendritic cells , 2009, Experimental & Molecular Medicine.

[14]  H. Hammad,et al.  Mechanism of action of clinically approved adjuvants. , 2009, Current opinion in immunology.

[15]  S. Endres,et al.  ISCOMATRIX Adjuvant Induces Efficient Cross-Presentation of Tumor Antigen by Dendritic Cells via Rapid Cytosolic Antigen Delivery and Processing via Tripeptidyl Peptidase II1 , 2009, The Journal of Immunology.

[16]  A. Mackensen,et al.  In situ analysis of the antigen-processing machinery in acute myeloid leukaemic blasts by tissue microarray , 2009, Leukemia.

[17]  H. Fujiwara,et al.  Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. , 2008, Blood.

[18]  N. Bhardwaj,et al.  KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity. , 2008, The Journal of clinical investigation.

[19]  C. Melief.  Cancer immunotherapy by dendritic cells. , 2008, Immunity.

[20]  T. H. van der Kwast,et al.  Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors. , 2008, Blood.

[21]  R. Kennedy,et al.  Multiple roles for CD4+ T cells in anti‐tumor immune responses , 2008, Immunological reviews.

[22]  J Philip McCoy,et al.  Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. , 2008, The Journal of clinical investigation.

[23]  M. Marcilla,et al.  Tripeptidyl peptidase II is dispensable for the generation of both proteasome‐dependent and proteasome‐independent ligands of HLA‐B27 and other class I molecules , 2008, European journal of immunology.

[24]  Axel Hoos,et al.  Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Russell Middaugh,et al.  Nanotechnology in vaccine delivery☆ , 2008, Advanced Drug Delivery Reviews.

[26]  A. Cooke,et al.  Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. , 2008, Critical reviews in immunology.

[27]  I. Svane,et al.  Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters , 2008, Cancer Immunology, Immunotherapy.

[28]  T. Tomasi,et al.  Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells , 2008, Cancer Immunology, Immunotherapy.

[29]  P. Chomez,et al.  GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives , 2007, Expert review of vaccines.

[30]  D. O’hagan.  MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection , 2007, Expert review of vaccines.

[31]  S. Amigorena,et al.  Phagocytosis and antigen presentation in dendritic cells , 2007, Immunological reviews.

[32]  Richard L. Miller,et al.  Resiquimod and other immune response modifiers as vaccine adjuvants , 2007, Expert review of vaccines.

[33]  A. Ribas.  Anti-CTLA4 Antibody Clinical Trials in Melanoma. , 2007, Update on cancer therapeutics.

[34]  K. Rock,et al.  Analysis of the Role of Bleomycin Hydrolase in Antigen Presentation and the Generation of CD8 T Cell Responses1 , 2007, The Journal of Immunology.

[35]  D. Kirn,et al.  Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. , 2007, Cancer research.

[36]  S. Aamdal,et al.  Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA , 2006, Cancer Gene Therapy.

[37]  D. Valmori,et al.  Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses. , 2006, Cancer research.

[38]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[39]  B. Monsarrat,et al.  Destructive Cleavage of Antigenic Peptides Either by the Immunoproteasome or by the Standard Proteasome Results in Differential Antigen Presentation1 , 2006, The Journal of Immunology.

[40]  E. Gilboa,et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.

[41]  K. Rock,et al.  Leucine Aminopeptidase Is Not Essential for Trimming Peptides in the Cytosol or Generating Epitopes for MHC Class I Antigen Presentation1 , 2005, The Journal of Immunology.

[42]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[43]  I. Davis,et al.  Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. , 2005, Blood.

[44]  J. Marshall,et al.  Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Smyth,et al.  Close encounters of different kinds: Dendritic cells and NK cells take centre stage , 2005, Nature Reviews Immunology.

[46]  J. Villadangos,et al.  Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. , 2005, Advances in immunology.

[47]  A. Goldberg,et al.  Pathway for Degradation of Peptides Generated by Proteasomes , 2004, Journal of Biological Chemistry.

[48]  B. Seliger,et al.  High Frequency of Functionally Active Melan-A–Specific T Cells in a Patient with Progressive Immunoproteasome-Deficient Melanoma , 2004, Cancer Research.

[49]  D. Persing,et al.  Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents , 2004, Expert opinion on biological therapy.

[50]  P. Kloetzel.  Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII , 2004, Nature Immunology.

[51]  A. Goldberg,et al.  Post-proteasomal antigen processing for major histocompatibility complex class I presentation , 2004, Nature Immunology.

[52]  Jacques Neefjes,et al.  A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. , 2004, Immunity.

[53]  S. Wagner,et al.  Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression , 2003, Melanoma research.

[54]  U. Ritz,et al.  Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  Concepción Marañón,et al.  An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope , 2003, Nature Immunology.

[56]  W. Baumeister,et al.  A giant protease with potential to substitute for some functions of the proteasome. , 1999, Science.

[57]  Günter J. Hämmerling,et al.  Selectivity of MHC-encoded peptide transporters from human, mouse and rat , 1994, Nature.

[58]  A. Goldberg,et al.  Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. , 1993, Nature.